Pharmacodynamics and biomarker correlates of imvotamab (IGM-2323), the first-in-class CD20xCD3 bispecific IgM antibody with dual mechanisms of action, in patients with advanced B cell malignancies Meeting Abstract
| Authors: | Hernandez, G. H.; So, J.; Logronio, K. A.; Kotturi, M. F.; Kim, W. S.; Armand, P.; Cheah, C. Y.; Gopal, A. K.; Flinn, I. W.; Gregory, G. P.; Matasar, M. J.; Nastoupil, L. J.; Diefenbach, C. S.; Yoon, S. S.; Ku, M.; Qazi, I.; Leabman, M. K.; Sison, I.; Keyt, B. A.; Takimoto, C. H.; Manley, T. J.; Budde, E. L. |
| Abstract Title: | Pharmacodynamics and biomarker correlates of imvotamab (IGM-2323), the first-in-class CD20xCD3 bispecific IgM antibody with dual mechanisms of action, in patients with advanced B cell malignancies |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 6436 |
| End Page: | 6438 |
| Language: | English |
| ACCESSION: | WOS:000893223206201 |
| DOI: | 10.1182/blood-2022-163235 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
